Spyre Therapeutics Inc (SYRE)

SG&A Expense Growth

5.95%

Quarterly · Period ending:

SYRE logo

SYRE SG&A Expense Growth

Latest reported5.95%
SYRE Quarterly SG&A Growth (QoQ) (0.00% → 5.95%)
High-resolution chart · PNG

SYRE sg&a expense growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Spyre Therapeutics Inc SG&A Expense Growth — Quarterly
Period endingSG&A Expense Growth
5.9488%
21.5095%
7.6712%
-1.2638%
-1.2894%
10.8904%
1.1551%
-7.4972%
-10.3923%
-8.7123%
63.9329%
-28.8344%
157.735%
1.983%
-28.8527%
-10.4167%
-13.5447%
22.4346%
-0.541%
0.2492%
7.3654%
-9.4872%
23.7659%
20.9124%
5.1794%
2.694%
0.8358%
12.8669%
16.7687%
-6.8149%
5.8238%
13.2604%
1.4211%
24.5145%
-23.2781%
27.7496%
0%
15.3734%
-0.7748%
-15.6454%
33.7705%
13.2426%
18.7362%
-35.8926%
150.6494%
34.8726%
-3.8285%
39.2324%
44.7531%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.